Should the elderly receive chemotherapy for node-negative breast cancer ? A cost-effectiveness analysis examining total and active life-expectancy outcomes.
This study determines the survival benefit and cost-effectiveness of adjuvant chemotherapy in elderly women with breast cancer.
In addition, the analysis measures the impact of substituting active life expectancy for survival in the clinical decision.
Patients and Methods
Two cohorts of women with estrogen receptor (ER)-negative, stage I breast cancer from age 60 to 80 years were monitored using a Markov process.
One group received standard chemotherapy following primary therapy, and the other had no postoperative treatment.
Data were derived from recently published clinical trials and a major meta-analysis.
Outcome included the average survival, active life-expectancy, and incremental cost/quality-adjusted life-year (cost/QALY).
Mots-clés Pascal : Tumeur maligne, Anticancéreux, Glande mammaire, Précoce, Glande mammaire pathologie, Analyse coût efficacité, Economie santé, Survie, Vieillard, Homme, Chimiothérapie, Traitement
Mots-clés Pascal anglais : Malignant tumor, Antineoplastic agent, Mammary gland, Early, Mammary gland diseases, Cost efficiency analysis, Health economy, Survival, Elderly, Human, Chemotherapy, Treatment
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 93-0464519
Code Inist : 002B02R02. Création : 199406.